1. International Union for Cancer Control (UICC)
2. American Society of Clinical Oncology (ASCO)
3. Global Cancer Institute (GCI), Boston, USA
4. Memorial Sloan Kettering Cancer Centre (MSKCC), New York, USA
5. ABC (Advanced Breast Cancer) Alliance, Europe
6. Amrita Institute of Medical Sciences and Research Institute, Kerala, India
7. Paras HMRI Hospital, Patna, India
Case 1 – Fortaleza, Brazil
§Q2 2019 Biopsy:
§Angiosarcoma
§RT 20 Gy
§Q2 2019:
§Weekly taxol + zometa
Case 1 – Fortaleza, Brazil
§Abdominal CT Q1 2020: L2 vertebra lesion and L iliac bone
§Lung CT Q1 2020: C7, T1-5, T7-8 and T10 vertebra lesions
Case 2 – Monterrey, Mexico
§47 year old female
§Healthy, no relevant personal or family history
§Clinical data
•Q3 2019: Self-detected left breast mass
•Q3 2019: Mammogram
2.6 cm tumor + at least 2 enlarged axillary lymph nodes; BIRADS 5
•Q3 2019: Breast core biopsy
̶Lobular carcinoma G2, LVI+, ER 100%, PR 30%, HER2 neg, Ki67 1%
•Q3 2019: MRI
̶5.8 cm tumor + 2 enlarged axillary lymph nodes + sternal lytic lesion
•Q3 2019: PET/CT
̶Left breast mass + multiple left enlarged axillary lymph nodes +2 sternal hypermetabolic lesions + S1 lytic lesion
Case 1 – Tbilisi, Georgia
§Q4 2019- Pelvic and MRI: Cervical lesion measured 3.5/4.5/4.4 cm. Parametrial invasion. Parailiac lymphadenopathy- 26-10mm lymph nodes.
§Chest and Abdominal CT- No evidence of disease spread.
§Pathology report: Squamous cancer of cervix G2
